Rhenman & Partners Asset Management Ab Axsome Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 122,600 shares of AXSM stock, worth $11.1 Million. This represents 0.92% of its overall portfolio holdings.
Number of Shares
122,600
Previous 127,600
3.92%
Holding current value
$11.1 Million
Previous $10.3 Million
7.24%
% of portfolio
0.92%
Previous 1.01%
Shares
6 transactions
Others Institutions Holding AXSM
# of Institutions
325Shares Held
37.7MCall Options Held
912KPut Options Held
855K-
Rtw Investments, LP New York, NY4.19MShares$380 Million6.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4MShares$362 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$299 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$214 Million34.46% of portfolio
-
Bvf Inc San Francisco, CA1.05MShares$94.9 Million2.99% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.89B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...